← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Prolx Pharmaceuticals Corporation
Tucson, AZ
$7,313,019
Total funding
6
Grants
Funding over time
peak $1.8M · FY2005–08$2M$1.5M$1M$500K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$7,313,019 · 6
By mechanism
R44$6,522,353 · 3
R43$790,666 · 3
Investigators at Prolx Pharmaceuticals Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Thioredoxin Inhibitor, PX-12, in Phase II Clinical Trial$996,940
R44 · FY2006 · CA
Thioredoxin Inhibitor, PX-12, in Phase II Clinical Trial$995,448
R44 · FY2007 · CA
Thioredoxin Inhibitor, PX-12, in Phase II Clinical Trial$973,839
R44 · FY2008 · CA
PI-3 kinase inhibitor PX-866 as anticancer therapy$835,847
R44 · FY2007 · CA
PI-3 kinase inhibitor PX-866 as anticancer therapy$790,869
R44 · FY2006 · CA
A Hypoxia Activated HIF-1 &Inhibitor for Cancer Therapy$649,996
R44 · FY2005 · CA
A Hypoxia Activated HIF-1 &Inhibitor for Cancer Therapy$649,618
R44 · FY2003 · CA
A Hypoxia Activated HIF-1 &Inhibitor for Cancer Therapy$629,796
R44 · FY2004 · CA
PX-12, A Molecularly Targeted Preventive Agent$206,101
R43 · FY2004 · CA
PX-12, A Molecularly Targeted Preventive Agent$199,740
R43 · FY2005 · CA
Anticancer redox inhibitor,Pleurotin$193,617
R43 · FY2005 · CA
PI-3 kinase inhibitor PX-866 as anticancer therapy$191,208
R43 · FY2005 · CA